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Abstract
Background:  Narcolepsy-cataplexy is characterized by excessive daytime sleepiness with recurrent episodes of
irresistible sleep, cataplexy, hallucinations and sleep paralysis. Its aetiology is unknown, but it is positively associated with
the human leukocyte antigens (HLA) in all studied populations. The purpose of the present study was to investigate the
association of HLA class II DRB1/DQB1 alleles with narcolepsy-cataplexy in Mexican Mestizo patients.
Methods: This is a case-control study of consecutive patients and ethnically matched controls. We included 32 patients
diagnosed with typical narcolepsy-cataplexy, of the National Institute of Neurology, of the Institute of Psychiatry and at
the Center of Narcolepsy at Stanford University. As healthy controls, 203 Mexican Mestizos were included. DRB1 alleles
were identified using sequence based typing. A PCR-SSOP reverse dot blot was used for DQB1 typing. Allele frequency
was calculated by direct counting and the significance of the differences was assessed using the Yates Chi square. Odds
ratio and confidence intervals were evaluated.
Results: HLA-DRB1*1501 (OR = 8.2; pc < 0.0001) and DQB1*0602 (OR = 8.4; pc < 0.0001) were found positively
associated with narcolepsy. When deleting DQB1*0602+ patients from the analysis, DQB1*0301 was also found increased
(OR = 2.7; p = 0.035; pc = NS). DQB1*0602/DQB1*0301 genotype was present in 15.6% of the cases (OR = 11.5; p =
0.00035), conferring a high risk. DRB1*0407 (OR = 0.2; p = 0.016 pc = NS) and DQB1*0302(OR = 0.4; p = 0.017, pc =
NS) were found decreased in the patients. The gender stratification analysis showed a higher risk in females carrying
DRB1*1501 (OR = 15.8, pc < 0.0001) and DQB1*0602 (OR = 19.8, pc < 0.0001) than in males (OR = 5.0 for both alleles;
p = 0.012, pc = NS for DRB1 & p = 0.0012, pc = 0.017 for DQB1). The susceptibility alleles found in Mexicans with
narcolepsy are also present in Japanese and Caucasians; DRB1*04 linked protection has also been shown in Koreans. A
stronger HLA association is suggested in females, in accordance with the sexual dimorphism claimed previously.
Conclusion:  This knowledge may contribute to a better understanding of the disease pathogenesis in different
populations. The evaluation of the risk to develop narcolepsy-cataplexy in carriers of the described alleles/genotypes may
also be possible. A larger sample should be analysed in Mexican and in other Hispanic patients to confirm these results.
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Background
Narcolepsy is a serious chronic neurological sleep disor-
der affecting between 0.02–0.05% of the general Cauca-
sian population [1]. It is characterized by excessive
daytime sleepiness, cataplexy, hypnagogic hallucination,
sleep paralysis, and nocturnal fragmented/disorganized
sleep [2,3]. Narcolepsy causes cognitive dysfunction, low
academic performance and interpersonal problems [4].
Cataplexy is a pathognomonic clinical symptom required
for the diagnosis of narcolepsy, according to the Interna-
tional Classification of Sleep Disorders [5]. It is a symp-
tom that occurs when the muscle tension, in various areas
of the body, is suddenly decreased involuntarily and lasts
from few seconds to several minutes. Cataplexy is gener-
ally induced by laughter, excitement anger, and other
emotional changes [5]. Mutations in genes of the hypocre-
tin (orexin) neurotransmitter system cause narcoleptic
symptoms in animal models [6]. Although most patients
with narcolepsy-cataplexy have a reduction of hypocretin
concentration in the cerebrospinal fluid [7], mutations or
polymorphisms in hypocretin-related genes are extremely
rare [8]. A potential autoimmune mechanism has been
suggested, supported by the finding that in most nar-
colepsy patients, 80–90% of hypocretin cells in the
hypothalamus were destroyed [9]. The lost of hypocretin
neurons [10] has also been shown in a few post-mortem
cases. In addition, the transcription of preprohypocretin
mRNA was significantly decreased in the brain of these
patients [11]. This wake-promoting neuropeptide is
involved in sleep regulation, energy homeostasis, reward-
seeking, learning, and memory; and it is also involved in
the body temperature regulation, endocrine function, and
the cardiovascular system, among other systems [12].
Recent studies also indicate that hypocretin/orexin neu-
rons can alter their intrinsic electrical activity according to
fluctuations in the levels of nutrients and appetite-regulat-
ing hormones [13].
Narcolepsy transmission is polygenic, environmentally
influenced and genetic factors play an important role in its
expression. Family studies indicate the presence of a 20–
40 times increased risk of disease expression in first-
degree relatives, and monozygotic twin studies showed
that concordance is partial (25–31%) [1]. Early onset
French and Chinese patients suffering from narcolepsy
have shown a positive family history as compared with
late-onset patients [14,15], suggesting that the disease
may be more likely due to genetic factors in this subgroup
of patients.
Based on the strong HLA association, family study segre-
gation [16,17] and the finding of reduction of hypocretin-
1 levels in the cerebrospinal fluid of DQB1*0602 positive
patients [18,19], an autoimmune mediated destruction of
hypothalamic neurons secreting hypocretin has been sug-
gested as the cause of the disease. However, serum autoan-
tibody markers have not been detected and no
immunological abnormalities have been found in
patients with narcolepsy [20].
The disease is strongly associated in Caucasians and Japa-
nese with the DRB1*1501-DQA1*0102-DQB1*0602
haplotype. In African Americans, it is associated with
DQB1*0602 haplotypes bearing different DRB1  alleles
(*1101 and *1503) suggesting that DQA1 and DQB1 play
a primary role in susceptibility [17]. DQB1*0602 rather
than  DRB1*1501 has been found increased in the
patients, indicating that the disease susceptibility allele or
locus is within, or, in the vicinity of the DQ region [21].
Haplotype analysis and contiguous genomic sequencing
across the region have identified no other candidate gene
[22]. Two-five fold increased risk in DQB1*0602
homozygous vs. heterozygote patients has been demon-
strated in different ethnic groups [23]. DQB1*0301/
*0602 carriers are also at an increased risk, whereas
DQB1*0602/*0601 and DQB1*0602/*0501 heterozy-
gotes have a lower disease risk [23-25].
Several authors reported that 85 to 95% of patients with
narcolepsy carry DQB1*0602 when cataplexy is clinically
typical or severe. However, only 40–60% of the patients
are DQB1*0602 when mild, atypical or no cataplexy exists
[25,26]. TNF alpha region has also been claimed to be
involved in susceptibility independently of class II loci
[27].
Genetic factors in other chromosomes have also been
implicated [28]. A gender dimorphism and a strong effect
of the catechol-O-methyltransferase (COMT) genes seem
to influence symptoms. COMT  genotype distribution
between male and female patients was associated with the
response to modafinil in Caucasians, since the optimal
dose of modafinil was approximately 100 mg lower in
females with narcolepsy, suggesting that females are better
responders to the drug [29].
The HLA genetic profile of Mexican and other Central
American patients has not been published; therefore the
aim of this study was to investigate the class II-DRB1/
DQB1 allele distribution in a group of sporadic Mexican
Mestizo patients with narcolepsy and to explore if the
HLA association is gender related.
Methods
Subjects
A total of 32 patients (14 males (45.17%) and 17 females
(54.83%) were included. (The gender of one patient was
unknown). All the cases were chosen and diagnosed
based on the International Classification of Sleep Disor-
ders (ICSD) [5] using clinical histories, nocturnal polys-BMC Medical Genetics 2008, 9:79 http://www.biomedcentral.com/1471-2350/9/79
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omnography, and Multiple Sleep Latency Tests. It is
important to emphasize that the inclusion and exclusion
criteria were given to every participant in the Narcolepsy
Component of the 13th International Histocompatibility
Workshop, and every centre must have used the same
questionnaire and the same classification given by the
experts [17]. The study was approved by the Ethics and
Research Committees of each hospital. An informed con-
sent was signed by every patient included in the study.
Nine patients were selected from the Sleep Clinic at The
Instituto Nacional de Neurologia in Mexico City, 12 were
diagnosed at Stanford University Sleep Centre, and 11
were diagnosed at the Hospital Medica Sur in Mexico City.
All patients were selected under exactly the same criteria in
terms of ethnicity and diagnosis. Two hundred and three
healthy controls belonging to the same population were
included for comparison. These controls were all selected
at the Department of Immunology and Immunogenetics
in Mexico City and had no personal or family antecedents
of narcolepsy. The patients and controls were all Mexican
Mestizos defined according to the criteria of the Instituto
de Investigaciones Antropologicas of the Universidad
Nacional Autonoma de Mexico, UNAM [30]. All of them
were Mexicans with at least parents, grandparents and
great-grandparents born in Mexico; having Hispanic last
names. Any individual with a non Hispanic background
was excluded from the study. This ethnic group is the
result of the admixture of Mediterranean, Black and
Native genes [30,31]. The patients diagnosed in the USA
followed exactly the same criteria, and most of them were
in fact, patients from Mexico City from a previous collab-
orative done by Mignot E and Baker H. (Personal Com-
munication). The controls were healthy subjects with no
history of HLA confirmed associated diseases. Subjects
with excessive daytime sleepiness, other sleep disorders,
circadian or mental disorders, medication or substance
abuse were carefully excluded. Each subject underwent a
detailed clinical interview and completed a set of ques-
tionnaires according to The International Classification of
Sleep Disorders [5].
HLA-DRB1 &DQB1 typing
All patients and controls were typed at the Immunogenet-
ics Department in Mexico City with the same technology
and under the same technical conditions for each tech-
nique used. Ten mL peripheral EDTA blood were drawn
from each patient coming from the Mexican Institutions.
DNA was isolated using proteinase K digestion; purifica-
tion was achieved with phenol chlorophorm and isopro-
panol was used for precipitation. DNA of patients
diagnosed at Stanford University, were sent to our labora-
tory in Mexico City for HLA typing. DQB1 was typed on
DNA samples from 32 patients, using a commercial kit
based on Polymerase Chain Reaction and hybridization
with membrane immobilized Sequence Specific Oligonu-
cleotide Probes (PCR-SSOP reverse dot blot). DRB1
Sequence Based Typing (SBT) was performed in all
patients using AlleleSEQR DRB1 kits, kindly donated by
Atria Genetics. DRB1 and DQB1 alleles were typed in the
control samples by PCR-SSOP using a chemiluminescent
detection method designed for the 13th IHW (Interna-
tional Histocompatibility Workshop) [32].
DRB1 typing was performed in 27/32 samples because the
amount of DNA was not enough. In one patient gender
was unknown; therefore gender stratification analysis
included only 31 patients.
Haplotype assignment was done on the basis of the very
well known DRB1-DQB1  linkage disequilibrium data
published by us in Mexican Mestizos [31]. It was assumed
that no blanks were present; when a single HLA allele was
found; in this case, the subject was considered
homozygous. Rare haplotype associations were taken into
account, only when the complementary haplotype was
perfectly defined.
Statistical Analysis
Allele frequency was calculated by direct counting. The
Chi square test with Yates correction was used to assess the
statistical difference of the HLA allele distribution
between patients and controls. Bonferroni correction of
the p value (pc) was done multiplying the p value by the
number of comparisons made (equal to the number of
tested alleles). This correction made more stringent the
statistical significance of the results. Odds ratio (OR), was
calculated when a significant association between the par-
ticular allele and the disease was found. Confidence inter-
val (CI) (95%) was defined for every statistical deviation
and is shown in each table. HLA related gender stratifica-
tion was done using the SPSS 11 software.
Analysis of DQB1*0602 negative patients
To assess whether HLA alleles, other than DQB1*0602
were associated with narcolepsy, the allelic frequency
between patients and controls was compared, after taking
out from the analysis the DQB1*0602 positive patients.
Results
HLA Association
Only two DRB1 alleles were found significantly deviated
in the patients (Table 1). DRB1*1501 was significantly
increased (OR = 8.2; CI = 3.9–17.6; p < 0.0001; pc <
0.0001). The frequency of DRB1*0407 was significantly
decreased in them (OR = 0.2; CI = 0.02–1.2; p = 0.016),
although the significance was lost after Bonferroni correc-
tion. DQB1*0602 which is in linkage disequilibrium with
DRB1*1501 was associated with susceptibility (OR = 8.4;
CI = 4.3–16.6; p < 0.001; pc < 0.001) and the frequency of
DQB1*0302 was decreased in the patients (Table 2).BMC Medical Genetics 2008, 9:79 http://www.biomedcentral.com/1471-2350/9/79
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Upon withdrawal from the analysis of DQB1*0602 posi-
tive patients and controls, DQB1*0301 was found associ-
ated with the disease (Table 3) since 9/11 remaining
patients were carriers of this allele (OR = 2.7; CI = 1.1–6.5;
p = 0.0035; pc = Non significant (NS). We calculated the
DQB1 genotype distribution in order to know the risk
conferred by different combinations (Table 4). Only two
genotypes were associated with narcolepsy: the highest
risk was conferred by the combination DQB1*0602/
DQB1*0301 (OR = 11.5; CI = 2.6–50.7; p = 0.00035),
present in 15.6% (5/32) of the patients. DQB1*0602/X
(excluding *0301) was also found significantly increased
with a lower risk (OR = 9.5; CI = 4.1–21.9; p < 0.0001).
This combination was positive in 50% of patients (16/
32). No DQB1*0602 homozygotes were found.
Gender Stratification
Although DRB1*1501 and DQB1*0602 were increased in
both, females and males, the risk was higher in females:
DRB1*1501 (OR = 15.8 CI = 4.5–55.7, p < 0.0001, pc <
0.0001 in females) vs. (OR = 5 CI = 1.6–15.4; p = 0.012,
pc = NS in males) and DQB1*0602, (OR = 19.8, CI = 5.9–
66.9, p < 0.0001, pc < 0.0001 in females) vs. (OR = 5, CI
= 1.9–13, p = 0.0012, pc = 0.017 in males). DQB1*0302
was found significantly decreased only in males (OR =
0.3, CI = 0.1–1, p = 0.043, pc = NS).
Table 1: HLA-DRB1 distribution in Mexican Mestizo patients with narcolepsy and in healthy controls.
Locus Total Patients Total Controls
DRB1* N = 27† AF% N = 203 AF% X2YO R ( C I ) p p c
0101 0 0 11 2.7 0.6
0102 0 0 17 4.2 1.3
0103 0 0 2 0.5 0.3
1001 1 1.8 3 0.7 0
1101 3 5.6 12 3 0.4
1102 0 0 4 1 0
1103 0 0 1 0.2 1.4
1104 2 3.7 9 2.2 0
1201 0 0 4 1 0
1301 0 0 9 2.2 0.3
1302 1 1.8 10 2.5 0
1303 2 3.7 4 1 1
1304 1 1.8 1 0.2 0.3
1305 0 0 1 0.2 1.4
1401 0 0 5 1.2 0
1402 2 3.7 14 3.4 0.1
1406 0 0 24 5.9 2.3
1501 15 27.8 18 4.4 35.6 8.2 (3.9–17.6) <0.0001 <0.0001
1502 2 3.7 5 1.2 0.6
1503 2 3.7 2 0.5 2.6
1504 1 1.8 0 0 1.4
1601 0 0 4 1 0
1602 1 1.8 21 5.2 0.5
0301 3 5.6 18 4.4 0
0302 0 0 3 0.7 0.1
0401 0 0 1 0.2 1.4
0402 0 0 7 1.7 0.1
0403 3 5.6 7 1.7 1.7
0404 3 5.6 17 4.2 0
0405 0 0 12 3 0.7
0407 1 1.8 60 14.8 5.8 0.2 (0.02–1.2) 0.016 NS
0410 0 0 2 0.5 0.3
0411 2 3.7 12 3 0
0701 4 7.4 27 6.7 0
0801 0 0 6 1.5 0.1
0802 3 5.6 51 12.6 1.6
0804 1 1.8 0 0 1.4
0806 1 1.8 0 0 1.4
0901 0 0 2 0.5 0.3
AF: allele frequency; X2Y: Chi2 value with Yates correction; OR: Odds Ratio; CI: Confidence Interval; pc: Bonferroni correction (the p value was 
multiplied by the total number of alleles tested); NS: Not significant; †5/32 patients were not typed for DRB1 locus.BMC Medical Genetics 2008, 9:79 http://www.biomedcentral.com/1471-2350/9/79
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Discussion
The results of this study are considered preliminary, due
to the small sample size. However, it is important to men-
tion that we are not "Hypothesis generating" but "hypoth-
esis testing". As demonstrated by many statistician experts
in the HLA field: "If an association is detected in the first
case, it can be tested and confirmed in the latter without
having to correct in multiple comparisons" [33]. Never-
theless, future studies in Hispanic admixed populations
are needed to confirm the presence of other HLA allele
associations. It is worth to mention, that DRB1/DQB1
association has been tested and repeatedly demonstrated
by many authors in different ethnic groups [23-25,34];
therefore, the associations shown here, are real. In this
study, we report on the genetic profile in a sample of nar-
coleptic Mestizo patients. DRB1*1501 (OR = 8.2; pc <
0.0001) and DQB1*0602 (OR = 8.4; pc < 0.0001) were
the strongest associated alleles found in narcoleptic Mexi-
cans, similarly to African, White Americans and different
Oriental groups [23-25,34-37]. Fifteen of the 27 DRB1
typed patients, were positive for DRB1*1501 (allele fre-
quency = 27.8 vs. 4.4% in the controls) and 21 of the 32
DQB1 typed patients were positive for DQB1*0602 (allele
frequency = 32.8% vs. 5.4% in the controls). In five DQB1
typed patients, DRB1 was not typed because of insuffi-
cient DNA, thus we were not able to assemble the DRB1-
DQB1  combinations in them. Interestingly, the
DRB1*1501-DQB1*0602 haplotype was present in most
of the DQB1*0602 positive patients but other DR2 allele
combinations were also found. Indeed, two narcoleptic
Table 2: HLA-DQB1 distribution in Mexican Mestizo patients with narcolepsy and in healthy controls.
Locus Total Patients Total Controls
DQB1* N = 32 AF% N = 203 AF% X2YO R ( C I ) p p c
0201 8 12.5 43 10.6 0.1
0301 16 25.0 100 24.6 0.0
0302 8 12.5 111 27.3 5.7 0.4 (0.2–0.9) 0.017 NS
0303 2 3.1 5 1.2 0.4
0402 5 7.8 60 14.8 1.7
0501 2 3.1 35 8.6 1.6
0502 0 0 5 1.2 0.1
0503 0 0 5 1.2 0.1
0601 0 0 4 1 0.0
0602 21 32.8 22 5.4 46.7 8.4 (4.3–16.6) <0.0001 <0.0001
0603 0 0 7 1.7 0.3
0604 0 0 7 1.7 0.3
0605 1 1.6 1 0.2 0.2
0609 1 1.6 1 0.2 0.2
AF: allele frequency; X2Y: Chi2 value with Yates correction; OR: Odds Ratio; CI: Confidence Interval; pc: Bonferroni correction (the p value was 
multiplied by the total number of alleles tested); NS: Not significant.
Table 3: HLA-DQB1 distribution in Mexican Mestizo DQB1*0602 negative patients and controls.
Locus Patients Controls
DQB1* ΛN = 11 AF% ςN = 181 AF% X2YO R ( C I ) p p c
0201 4 18.2 38 10.5 0.6
0301 11** 50 97 26.8 4.4 2.7 (1.1–6.5) 0.035 NS
0302 3 13.6 104 28.7 1.7
0303 0 0 5 1.4 0.2
0402 2 9.1 55 15.2 0.2
0501 1 4.5 33 9.1 0.1
0502 0 0 5 1.4 0.2
0503 0 0 5 1.4 0.2
0601 0 0 4 1.1 0.3
0603 0 0 7 1.9 0
0604 0 0 7 1.9 0
0605 1 4.5 1 0.3 1.4
0609 0 0 1 0.3 1.4
AF: allele frequency; X2Y: Chi2 value with Yates correction; OR: Odds Ratio; CI: Confidence Interval; pc: Bonferroni correction (the p value was 
multiplied by the total number of alleles tested); NS: Not significant; Λ: 11/32 total patients were DQB1*0602 negative; ς: 181/203 total controls 
were DQB1*0602 negative. ** this number includes two DQB1*0301 homozygotes.BMC Medical Genetics 2008, 9:79 http://www.biomedcentral.com/1471-2350/9/79
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patients had DRB1*1502-DQB1*0602 and two had
DRB1*1503-DQB1*0602. A DRB1*1503 but not
DRB1*1502 association with DQB1*0602 has been
reported in patients from Martinique [38] and in African
Americans [23]. These results show, beyond doubt, that
DQB1*0602, rather than DRB1*1501 is the major nar-
colepsy susceptibility allele in Mestizos. Interestingly,
none of the DR52 associated-DQB1*0602 haplotypes
were found in Mexican patients, but their frequency is low
in the general healthy population. As an example, in 160
Mexican Mestizo healthy individuals typed in our labora-
tory, the haplotype frequency was 0.31% for each of the
following combinations: DRB1*1101-DQB1*0602,
DRB1*1201-DQB1*0602 and DRB1*1301-DQB1*0602
(unpublished data). Some of these haplotypes have been
reported in narcoleptic patients in other populations,
most notably in African Americans [23].
No increase in DQB1*0602 homozygosity was found, as
previously reported in White Americans and in African
American patients, in whom a two to four fold higher risk
has been described, compared to heterozygotes [23]. The
same has been shown in Japanese patients [24]. This fact
cannot be explained only based on the different allele fre-
quencies of DQB1*0602 across ethnic groups, since the
frequency shown in Japanese (AF = 6.4%) [24] was similar
to the one found in the control group of the present study
(AF = 5.5%). The lack of homozygote patients may be due
to the reduced number of cases. Thus, again, a larger
number is needed to confirm these results.
As in other populations, other DQB1  alleles, beside
DQB1*0602, influence narcolepsy susceptibility [24,39].
The analysis of DQB1 distribution in DQB1*0602 nega-
tive patients showed that DQB1*0301 (OR = 2.7, p =
0.03) was significantly increased in this subgroup of
patients. DQB1*0301 had also the second strongest sus-
ceptibility effect, after DQB1*0602 in Africans, Japanese
and White Americans [24]. In Mexican patients,
DQB1*0301 occurred in the context of several HLA hap-
lotypes that included DRB1*1101, *1303, *1304, *0806
and *1602; however the number of patients in this group
was insufficient to perform additional comparisons and
to explain the possible independent contribution of the
mentioned DRB1 alleles to susceptibility. None of these
patients had the DRB1*04-DQB1*0301, found associated
in White Americans [24]. Genotype distribution in
patients and controls showed that DQB1*0602/
DQB1*0301 conferred the highest risk for susceptibility
(OR = 11.4) compared to DQB1*0602/X (non *0301)
(OR = 9.4). The former combination was also described as
the one with the highest risk for the development of nar-
colepsy, across three different ethnic groups [24].
DRB1*0407, which is the most frequent allele in Mexican
population, seemed to be linked to protection in the
present study. This allele is in strong linkage disequilib-
rium with DQB1*0302 in Mexicans and the haplotype
frequency of DRB1*0407-DQB1*0302 is 13.1% [31]. In
Koreans DRB1*0406-DQB1*0302 was found protective
in patients with narcolepsy [39]. None of these studies
confirmed a possible effect of DRB1*04 in susceptibility
as previously shown in Whites and Japanese [24]. It may
be claimed that the DQB1 locus may also be involved in
protection, since in Korean as well as in Mexican patients,
DQB1*0302 was decreased, although combined with
*0406 in Koreans and with *0407 in Mexicans.
DQB1*0601 has also been associated with protection in
Koreans [25,39] and Japanese [40], but the latter was not
related with protection in Mexicans, perhaps due to its
low frequency (AF = 0.5%) [31]. Similar findings have
been published recently in Koreans, where again,
DRB1*0406 was found negatively associated and
DQB1*0301 was described as a susceptibility allele. The
authors claim based on their own work, and previous
work, that a remarkable consistency of the HLA associa-
tion pattern across multiple ethnic groups and cultures
exists [41]. Thus, even if our sample size is small and the
results of protection and secondary association may be
regarded as preliminary, our data are consistent with
those published [21,23-26,39,41].
Interestingly, the overall positive rate for DQB1*0602 in
Mexican patients was 65.6%, while in Japanese, White
Americans and African Americans; the rate is between 75–
80% [24]. To analyse if this difference was significant or
not, we performed a statistical comparison between
patients and controls from the present study and those
Table 4: HLA-DQB1 genotypes distribution in Mexican Mestizo patients with narcolepsy and controls.
DQB1* Genotypes N = 32 GF% N = 203 GF% X2YO R ( C I ) p
0602/X(not *0301) 16 50.0 19 9.4 32.9 9.5(4.1–21.9) <0.0001
0602/0301 5 15.6 3 1.5 12.8 11.5(2.6–50.7) 0.00035
0301/0301 2 6.3 15 7.4 0.01
0301/X(no 0602 or 0301) 9 28.1 82 40.4 1.3
X/X 2 6.3 99 48.8 18.7 0.1(0.0–0.4) <0.0001
GF: genotype frequency; X2Y: Chi2 value with Yates correction; OR: Odds Ratio; CI: Confidence Interval.BMC Medical Genetics 2008, 9:79 http://www.biomedcentral.com/1471-2350/9/79
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from the Mignot et al. study [24]. No significant differ-
ence, regarding DQB1*0602 distribution, was found
between Japanese and Mexican controls but we did find a
significant deviation when comparing Mexican controls
with White or African Americans healthy people (p =
0.001 and p = 0.00000001, respectively). These differ-
ences are due, undoubtedly, to the lower frequency of
DQB1*0602 existing in the general Mexican population
[42], which is similar to the one found in Orientals, but it
is lower than the frequency in Caucasian and African
Americans [43]. The lower frequency of the DQB1*0602
allele in Mexican patients compared with African (p =
0.0007), Caucasian (p = 0.003) and Japanese (p = 0.0009)
patients, is due to our small number of cases.
Gender stratification showed a differential distribution of
DRB1 and DQB1 alleles. The patients selection was unbi-
ased since no significant difference was found when distri-
bution of males Vs. females was compared (Z = 0.561, p =
0.29). To demonstrate if the gender selection among the
controls was biased, we performed several analyses com-
paring the mean allele frequency in the overall control
group with the frequency for HLA DQB1*0602 among
male and female patients. However, the distribution of
DQB1*0602 alleles among female and male controls was
found in the limit of the significance (X2Y = 3.841, p =
0.05; data not shown). Therefore, it must be mentioned
that even if the p value was p = 0.05, the control selection
may have been biased. When HLA distribution was com-
pared matching for gender, DRB1*1501 (OR = 15.8; pc <
0.0001) and DQB1*0602 (OR = 19.8; p < 0.0001)
showed a higher risk in female patients, although the
same alleles were significantly increased in males, but
with less intensity. This stronger female HLA association
was described for the first time. However, it is important
to confirm these data with a larger sample size and in dif-
ferent ethnic groups. Thus, the gender association
reported here should be regarded as preliminary. Even if
we have a stronger HLA DRB1/DQB1  association in
females, this does not imply, by any means, that females
are more or less affected than males; this only means that
there is a stronger HLA genetic predisposition to nar-
colepsy in females than in males. A better response in
affected women to certain drugs [29] is not contradictory
at all, with the HLA/female association.
The explanation for this gender specific association is not
clear, but a sexual dimorphism and a strong effect of the
COMT genotype on disease severity and response to
modafinil have been shown [44]. Females with nar-
colepsy with high COMT activity fell asleep twice as fast as
those with low COMT activity during the multiple sleep
latency test, while the opposite was true for men [45]. A
gender difference in body weight gain and leptin signaling
in hypocretin/orexin deficient mouse models has been
also claimed [46]. Obesity was more prominent in
females in both preprohypocretin knockout mice and
orexin/ataxin-3 transgenic narcoleptic mice and was asso-
ciated with higher serum leptin levels, suggesting a partial
leptin resistance [46].
Conclusion
In conclusion, this is the first study reported in Mexican
patients with narcolepsy-cataplexy; the profile of HLA
class II allele associations was found to be complex. As in
other diseases such as type I diabetes, multiple sclerosis
and others, studied by our group in Mexican Mestizos, the
HLA pattern in these diseases was somewhat distinct from
the association typically found in Caucasians or Blacks
and Orientals [47,48], illustrating the importance of ana-
lysing MHC associations in populations with different
ethnic backgrounds. We also demonstrated an HLA asso-
ciated sexual dimorphism in this population and a protec-
tive allele effect which was also shown in some Oriental
populations. Insights on the different HLA associations in
different ethnic groups may prove to be an important
asset in the investigation of genetic factors and the molec-
ular mechanisms of disease expression. This knowledge
may be important for the design of predictive, therapeutic
and perhaps preventive approaches.
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